Objective To explore the influencing factors of hospitalization in patients with mild active Crohn's disease or in clinical remission during long-term followup.Methods This was a prospective cohort study.From Augu...Objective To explore the influencing factors of hospitalization in patients with mild active Crohn's disease or in clinical remission during long-term followup.Methods This was a prospective cohort study.From August 5,2013 to January 5,2015,123 patients with mild active Crohn's disease or in clinical remission visited the Department of Gastroenterology.展开更多
Objective To evaluate the efficacy and safety of thalidomide(100 to 200 mg per day)in the treatment of adult refractory Crohn’s disease(CD).Methods From July 2008 to February 2013,29 refractory CD patients were enrol...Objective To evaluate the efficacy and safety of thalidomide(100 to 200 mg per day)in the treatment of adult refractory Crohn’s disease(CD).Methods From July 2008 to February 2013,29 refractory CD patients were enrolled in thalidomide(100 to 200 mg per day)cohort study.The clinical activity was evaluated by展开更多
文摘Objective To explore the influencing factors of hospitalization in patients with mild active Crohn's disease or in clinical remission during long-term followup.Methods This was a prospective cohort study.From August 5,2013 to January 5,2015,123 patients with mild active Crohn's disease or in clinical remission visited the Department of Gastroenterology.
文摘Objective To evaluate the efficacy and safety of thalidomide(100 to 200 mg per day)in the treatment of adult refractory Crohn’s disease(CD).Methods From July 2008 to February 2013,29 refractory CD patients were enrolled in thalidomide(100 to 200 mg per day)cohort study.The clinical activity was evaluated by